ProBioGen, Emergent BioSolutions Partner in Vaccine Manufacturing - - BioPharm International

ADVERTISEMENT

ProBioGen, Emergent BioSolutions Partner in Vaccine Manufacturing



ProBioGen has formed an agreement with Emergent BioSolutions for a non-exclusive commercial multiproduct license and option agreement under which Emergent will be granted broad access to ProBioGen’s avian AGE1.CR cell line. Previously, ProBioGen had granted an exclusive license to Emergent for four indications and also conducted process development work for Emergent.  As a result of the new agreement, ProBioGen’s relationship with Emergent is now extended to include additional infectious disease targets, with the option to expand to numerous further indications. The commercial licenses include milestones and royalty payments. Financial details were not disclosed.

Source: ProBioGen

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines

Click here